Biliary Atresia Treatment Market to Surpass US$ 1,527.9 Million by 2028 - Coherent Market Insights

Global Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 910.7 Mn in 2021 and is expected to exhibit a CAGR of 7.7% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Increasing research to develop safe and effective drugs for biliary atresia is expected to propel the growth of the global biliary atresia treatment market over the forecast period. For instance, as of October 2021, Odevixibat, a selective inhibitor of ileal bile acid transporter (IBAT), is undergoing a double-blind, randomized, placebo-controlled, phase III study to investigate its efficacy in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

Global Biliary Atresia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has highly impacted research and clinical trials of biliary atresia. They have been highly impacted due to the lack of new sample collections.

Moreover, according to an article published by American Association for the Study of Liver Diseases, substantial decrease in donations with unprecedented financial challenges and the cancellation of all fundraising events, will certainly impact pediatric liver research funding

On a positive note, the COVID-19 pandemic has strengthened the pediatric hepatology community. For instance, The Society of Pediatric Liver Transplantation–The Transplantation Society and North American Society for Pediatric Gastroenterology, Hepatology & Nutrition has established a joint national registry for COVID-19 in kids with post–liver transplantation and chronic liver disease.

Browse 28 Market Data Tables and 24 Figures spread through 191 Pages and in-depth TOC on “Global Biliary Atresia Treatment Market”- Forecast to 2028, Global Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/biliary-atresia-treatment-market-4779

Moreover, efforts undertaken by organizations to design and carry out studies on rare diseases are also expected to aid in the growth of the global biliary atresia treatment market over the forecast period. For instance, ‘The Childhood Liver Disease Research Network’ (ChiLDReN) is a collaborative team of doctors, nurses, medical facilities, research coordinators, and patient support organizations. Moreover, the network aims to improve the lives of youngsters and families dealing with rare liver diseases. The ChiLDReN Network was formed in October 2019, to support the invention of the latest diagnostic, etiologic, treatment options for children with liver disease, and people who undergo liver transplantation.

Key Takeaways of the Global Biliary Atresia Treatment Market:

• The global biliary atresia treatment market is expected to exhibit a CAGR of 7.7% during the forecast period, due to increasing research and pipeline of drugs. For instance, Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases – biliary atresia and is in its phase 2b of clinical trial. Maralixibat inhibits the apical sodium-dependent bile acid transporter (ASBT), causing more bile acids to be excreted in the feces, leading to decreased degrees of bile acids systemically, thereby potentially lowering bile acid mediated liver damage and associated effects and complications.
• In terms of disease type, type III segment is expected to hold the largest market share in the global biliary atresia treatment market over the forecast period, due to its high incidence. For instance, according to an article published by Science Direct in 2016, type III i.e. porta hepatis affects approximately (~ 85%) of biliary atresia patients.
• Among treatment type, surgery is estimated to hold the largest market share in the global biliary atresia treatment market in 2021. As there is no cure for biliary atresia, the main treatment is a surgery called Kasai procedure. In this surgery, the damaged bile ducts are removed from the liver and replaced with a piece of the patient’s small intestine. This surgery provides a path that allows bile to drain from the liver.
• On the basis of region, Asia Pacific is estimated to grow with a higher CAGR during the forecastperiod in the global biliary atresia treatment market, owing to the high prevalence of biliary atresia in this region. For instance, according to an article published in PubMed in June 2019, biliary atresia appears to be more common in Southeast Asia, with an incidence of about 1:5,000 live births, in comparison to North America and Western Europe, which have an incidence of 1:10,000-15,000 births.
• Major players operating in the global bone cancer drug market include AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals